Cargando…
Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing
Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical indication. Even though many repurposed drugs have been found serendipitously in the past, the increasing availability of large volumes of biomedical data h...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401966/ https://www.ncbi.nlm.nih.gov/pubmed/37546930 http://dx.doi.org/10.1101/2023.07.21.550045 |
_version_ | 1785084780220514304 |
---|---|
author | Liu, Fang Patt, Andrew Chen, Chloe Huang, Ruili Xu, Yanji Mathé, Ewy A. Zhu, Qian |
author_facet | Liu, Fang Patt, Andrew Chen, Chloe Huang, Ruili Xu, Yanji Mathé, Ewy A. Zhu, Qian |
author_sort | Liu, Fang |
collection | PubMed |
description | Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical indication. Even though many repurposed drugs have been found serendipitously in the past, the increasing availability of large volumes of biomedical data has enabled more systemic, data-driven approaches for drug candidate identification. At National Center of Advancing Translational Sciences (NCATS), we invent new methods to generate new data and information publicly available to spur innovation and scientific discovery. In this study, we aimed to explore and demonstrate biomedical data generated and collected via two NCATS research programs, the Toxicology in the 21st Century program (Tox21) and the Biomedical Data Translator (Translator) for the application of drug repurposing. These two programs provide complementary types of biomedical data from uncovering underlying biological mechanisms with bioassay screening data from Tox21 for chemical clustering, to enrich clustered chemicals with scientific evidence mined from the Translator towards drug repurposing. 129 chemical clusters have been generated and three of them have been further investigated for drug repurposing candidate identification, which is detailed as case studies. |
format | Online Article Text |
id | pubmed-10401966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-104019662023-08-05 Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing Liu, Fang Patt, Andrew Chen, Chloe Huang, Ruili Xu, Yanji Mathé, Ewy A. Zhu, Qian bioRxiv Article Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical indication. Even though many repurposed drugs have been found serendipitously in the past, the increasing availability of large volumes of biomedical data has enabled more systemic, data-driven approaches for drug candidate identification. At National Center of Advancing Translational Sciences (NCATS), we invent new methods to generate new data and information publicly available to spur innovation and scientific discovery. In this study, we aimed to explore and demonstrate biomedical data generated and collected via two NCATS research programs, the Toxicology in the 21st Century program (Tox21) and the Biomedical Data Translator (Translator) for the application of drug repurposing. These two programs provide complementary types of biomedical data from uncovering underlying biological mechanisms with bioassay screening data from Tox21 for chemical clustering, to enrich clustered chemicals with scientific evidence mined from the Translator towards drug repurposing. 129 chemical clusters have been generated and three of them have been further investigated for drug repurposing candidate identification, which is detailed as case studies. Cold Spring Harbor Laboratory 2023-07-25 /pmc/articles/PMC10401966/ /pubmed/37546930 http://dx.doi.org/10.1101/2023.07.21.550045 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) . |
spellingShingle | Article Liu, Fang Patt, Andrew Chen, Chloe Huang, Ruili Xu, Yanji Mathé, Ewy A. Zhu, Qian Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title | Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title_full | Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title_fullStr | Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title_full_unstemmed | Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title_short | Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing |
title_sort | exploring ncats in-house biomedical data for evidence-based drug repurposing |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401966/ https://www.ncbi.nlm.nih.gov/pubmed/37546930 http://dx.doi.org/10.1101/2023.07.21.550045 |
work_keys_str_mv | AT liufang exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT pattandrew exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT chenchloe exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT huangruili exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT xuyanji exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT matheewya exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing AT zhuqian exploringncatsinhousebiomedicaldataforevidencebaseddrugrepurposing |